SERMO unveils first global physician-to-physician drug ratings tool
- Details
- Category: Business
SERMO, the largest global social network for physicians with 650,000 members worldwide, has announced the groundbreaking new "Drug Ratings" tool. Drug Ratings is the first and only global peer-to-peer prescription drug review system sourced exclusively from verified licensed physicians. With more than a quarter million ratings and 20,000 comments from doctors worldwide to date in the beta release, the Ratings platform is quickly becoming the largest global database of physician feedback on drugs.
Merck acquires Grzybowski Scientific Inventions to expand chemical synthesis offering
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced the acquisition of Grzybowski Scientific Inventions (GSI), a company that developed the revolutionary computer-aided retro-synthesis tool, Chematica. Chematica uses advanced reaction rules and proprietary algorithms to identify synthesis pathways that meet user-defined constraints.
Abbott announces CE Mark and first use of the world's first smartphone compatible insertable cardiac monitor
- Details
- Category: Abbott
Abbott (NYSE: ABT) today announced CE Mark and first use of the new Confirm RxTM Insertable Cardiac Monitor (ICM), the world's first smartphone compatible ICM that will help physicians identify difficult to detect cardiac arrhythmias, including atrial fibrillation (AF), to help guide therapy. Since CE Mark approval, adoption of the device has been strong and implants have occurred in 10 countries across Europe.
Novartis exercises exclusive option agreement with Conatus for the treatment of NASH
- Details
- Category: Novartis
Novartis announced today that it has notified Conatus Pharmaceuticals Inc., of its exercise of the option to an exclusive license for the global development and commercialization of emricasan, under the option, collaboration and license agreement signed with Conatus on December 19, 2016. The exercise of the option with Conatus, a biotechnology company focused on the development of novel medicines to treat liver disease, and
Grants4Apps Accelerator and new Dealmaker now open for submissions
- Details
- Category: Business
The Grants4Apps Accelerator Berlin is back and this time with an additional track for the mature startups out there: The Dealmaker. Up to five startups will be selected for the 100-day Accelerator program in Berlin. The new Dealmaker is all about quality facetime between you and Grants4Apps experts for one full day.
AstraZeneca marks a key milestone with the ‘topping out’ of new global R&D centre and HQ in Cambridge, UK
- Details
- Category: AstraZeneca
AstraZeneca marks a key milestone in its successful move to Cambridge, UK, with the 'topping out' of its new, state-of-the-art, strategic R&D centre and global corporate headquarters at the heart of the Cambridge Biomedical Campus (CBC). The Company, including its biologics research and development arm, MedImmune, already has 2,000 employees actively engaged in the city’s vibrant scientific, academic, clinical and business community.
New data at AAN reinforce clinical benefit of Roche's OCREVUS™ (ocrelizumab) for relapsing and primary progressive multiple sclerosis
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from the OCREVUS™ (ocrelizumab) clinical trial programmes will be presented during the 69th American Academy of Neurology (AAN) Annual Meeting in Boston, Massachusetts. The presentations will highlight new efficacy and safety analyses from the OCREVUS Phase II and Phase III trials, as well as from the open-label extensions.
More Pharma News ...
- Merck divests Biosimilars business to Fresenius
- Novartis real-world data at AAN confirms benefit of Gilenya® on four key measures of disease activity in relapsing MS
- Pfizer unveils ATLAS®, an interactive, user-friendly website that provides global antibiotic resistance surveillance data across 60 countries
- Merck partners with University of California, San Diego (UCSD) to fight Neglected Tropical Diseases
- Lilly to present data for galcanezumab for the prevention of migraine at the American Academy of Neurology (AAN) annual meeting
- Novartis expands development programs for NASH through clinical collaboration with Allergan
- Bristol-Myers Squibb enters into separate agreements with Biogen and Roche to License anti-eTau and anti-myostatin compounds